When Starting GLP-1: Discontinue Gliclazide and Reduce Basal Insulin by 10-20%
When initiating a GLP-1 receptor agonist in a patient on both insulin and gliclazide (a sulfonylurea), you should discontinue the gliclazide immediately and reduce the basal insulin dose by 10-20% if the A1C is <8% (<64 mmol/mol). 1, 2
Gliclazide Management
The 2025 ADA Standards of Care and 2022 ADA/EASD consensus are unequivocal: sulfonylureas like gliclazide should be discontinued once insulin is started 2. This principle extends to GLP-1 RA initiation because both insulin and sulfonylureas independently cause hypoglycemia, and adding a GLP-1 RA to this combination creates unacceptable hypoglycemia risk 3, 4.
Key Action Points:
- Stop gliclazide completely when starting the GLP-1 RA
- Do not taper—discontinue immediately
- The GLP-1 RA will provide glucose-dependent insulin secretion without the hypoglycemia risk of sulfonylureas 4
Insulin Dose Adjustment Algorithm
If A1C <8% (<64 mmol/mol):
- Reduce basal insulin by 4 units/day OR 10% of the current dose 1
- This prevents hypoglycemia as the GLP-1 RA takes effect
- More conservative reduction (20%) is supported by research evidence 5, 6
If A1C ≥8% (≥64 mmol/mol):
- May continue current basal insulin dose initially 1
- Monitor closely and adjust downward as needed based on glucose readings
- The higher baseline A1C provides a safety buffer against hypoglycemia
For Prandial (Bolus) Insulin:
- Reduce by 30-40% if the patient is on mealtime insulin 6
- This is more aggressive than basal reduction because GLP-1 RAs have pronounced postprandial effects
- Consider starting with the largest meal first
Practical Implementation
Week 1-2:
- Discontinue gliclazide immediately
- Reduce basal insulin by 10-20% (if A1C <8%)
- Start GLP-1 RA at lowest dose per manufacturer guidelines
- Increase glucose monitoring frequency (at least 3-4 times daily)
Week 2-4:
- Titrate GLP-1 RA per manufacturer protocol
- Further reduce insulin by 10-20% if experiencing hypoglycemia
- Monitor for gastrointestinal side effects from GLP-1 RA
Month 2-3:
- Reassess insulin requirements as GLP-1 RA reaches therapeutic dose
- Expect continued insulin dose reductions 7
- Target fasting glucose 80-130 mg/dL
Critical Pitfalls to Avoid
Do NOT:
- Continue gliclazide "at a lower dose"—this still carries hypoglycemia risk
- Wait to see how the patient responds before adjusting insulin—proactive reduction prevents hypoglycemia
- Reduce insulin doses if A1C >10% or glucose >300 mg/dL at baseline (these patients need the insulin) 1
DO:
- Provide glucagon prescription for emergency hypoglycemia 1
- Educate patients to test for ketones if glucose >250 mg/dL (GLP-1 RAs reduce insulin requirements, risking DKA if insulin reduced too aggressively)
- Expect 10-20 unit reduction in total basal insulin over 24 weeks 7
Evidence Quality Note
The guideline recommendations 1, 2 are clear about sulfonylurea discontinuation with insulin. The specific insulin reduction percentages come from both guideline algorithms and high-quality research 7, 5, 6. The 2024 VA study 3 demonstrated that 38.9% of patients discontinued sulfonylureas and 57.3% reduced insulin doses when GLP-1 RAs were added, validating this approach in real-world practice.